Enhancing the Rapid Engineering of Vesicular Stomatitis Virus Using Synthetic Virology

Floker Manal^*
*Correspondence: Floker Manal, Department of Hygiene and Environmental Medicine, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany, Email:

Introduction

Vesicular Stomatitis Virus is a member of the Rhabdoviridae family and has gained considerable attention in recent years due to its potential applications in both research and medicine. Synthetic virology, a field that combines molecular biology, virology, and genetic engineering, has allowed for the rapid engineering of viruses like VSV, providing valuable tools for studying viral dynamics, developing vaccines, and designing oncolytic virotherapy strategies. The ability to manipulate and engineer VSV quickly has significant implications for the development of therapeutic interventions and virus-based applications. This article delves into the advancements in synthetic virology that have facilitated the rapid engineering of VSV, its potential applications, and the challenges and future directions of this rapidly evolving field [1,2].

Description

VSV is an RNA virus that typically infects livestock, causing diseases such as vesicular stomatitis, which is characterized by fever, blisters, and lesions in animals. Though it is not commonly harmful to humans, it serves as an ideal model for studying RNA viruses due to its relatively simple structure and wellcharacterized genome. The virus is enveloped and carries a negative-sense RNA genome, making it a useful model for studying viral replication, assembly, and interactions with host cells.

One of the reasons VSV has gained prominence in synthetic virology is its ability to be engineered in a variety of ways. VSV’s genome can be readily manipulated to create recombinant viruses with desired genetic traits, making it a versatile platform for both basic research and applied therapeutic strategies. The virus's capacity to infect a wide range of host cells, including human cells, also makes it an attractive candidate for exploring virus-based therapies. The engineering of VSV has proven to be particularly valuable in the context of creating viral vectors for gene delivery, studying viral mechanisms, and developing novel oncolytic virotherapies. By modifying the virus to express foreign genes, such as tumor-targeting proteins or immunomodulatory molecules, researchers can harness the power of VSV to deliver therapeutic genes or selectively target cancer cells. The ability to rapidly and precisely engineer VSV enhances the potential of this virus as a tool in biomedicine [3-5].

Conclusion

The rapid engineering of Vesicular Stomatitis Virus through synthetic virology has unlocked new possibilities in viral research and therapy. Advances in genome manipulation, high-throughput screening, and viral production techniques have made it easier and faster to create engineered VSV strains with desired properties. The potential applications of engineered VSV in medicine, particularly in oncolytic virotherapy, gene therapy, and vaccine development, hold great promise for improving human health. Despite the challenges that remain, ongoing advancements in synthetic virology are likely to continue driving progress in the development of VSV-based therapeutic solutions. As these technologies evolve, VSV is poised to become an even more valuable tool in both basic research and clinical applications.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Chua, Gilbert T., Joshua Sung Chih Wong, Ivan Lam and Polly Po Ki Ho, et al. "Clinical characteristics and transmission of COVID-19 in children and youths during 3 waves of outbreaks in Hong Kong." JAMA Netw Open 4 (2021): 218824-218824.

   Google Scholar, Crossref, Indexed at

2. Feldman, Charles and Ronald Anderson. "The role of co-infections and secondary infections in patients with COVID-19." Pneumonia 13 (2021): 1-15.

   Google Scholar, Crossref, Indexed at

3. Shen, Xu-Rui, Rong Geng, Qian Li and Ying Chen, et al. "ACE2-independent infection of T lymphocytes by SARS-CoV-2." Signal Transduct Target Ther 7 (2022): 83.

   Google Scholar, Crossref, Indexed at

4. Billard, Marie-Noëlle and Louis J. Bont. "Quantifying the RSV immunity debt following COVID-19: A public health matter." Lancet Infect Dis 23 (2023): 3-5.

   Google Scholar, Crossref, Indexed at

5. Messacar, Kevin, Rachel E. Baker, Sang Woo Park and Hai Nguyen-Tran, et al. "Preparing for uncertainty: Endemic paediatric viral illnesses after COVID-19 pandemic disruption." Lancet 400 (2022): 1663-1665.

   Google Scholar, Crossref, Indexed at